Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation™ platform, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in the hospital and beyond.
Joe Kiani founded Masimo in 1989 as a private "garage start-up" company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry, the measurement of the oxygen saturation of arterial blood. His solution, Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies.
Today, Masimo SET® helps clinicians monitor more than 200 million patients in healthcare settings around the world each year, and is the primary pulse oximetry technology at 9 of the top 10 hospitals as ranked in the 2021-2022 U.S. News & World Report Best Hospitals Honor Roll. Masimo is publicly traded and employs more than 8,000 people worldwide. Licensing agreements allow Masimo technology to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Medical, Spacelabs, and Zoll. Throughout its more than 30-year journey, Masimo’s mission – to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications – has remained strong. In 2022, Masimo acquired Sound United, a leading developer of premium consumer sound and home integration technologies, adding to its broad portfolio of hospital and home medical technology and wellness solutions.
Commitment to Reliable and Accurate Healthcare Data
As a global leader in medical technologies, Masimo is committed to providing products that serve all patients, regardless of age, sex, race, ethnicity, or skin color. Recent media coverage has called into question the reliability of pulse oximetry in people with darker skin pigmentation.
Masimo SET® pulse oximetry performs accurately on patients of all skin colors, with an analysis of internal data presented at the 2022 Society of Technology in Anesthesia meeting showing no clinically significant difference in the accuracy or bias between black and white subjects. Clinicians and patients can remain confident in the performance of Masimo SET® pulse oximetry technology on both dark- and light-skinned patient populations.
We take this issue very seriously and are currently pursuing prospective clinical studies to a) confirm our laboratory data showing excellent accuracy across all skin tones and b) continue to improve both accuracy and reliability.
We urge all pulse oximeters to meet the same minimum accuracy requirements as current medical-grade pulse oximeters in order to provide correct and reliable healthcare information to patients regardless of skin color, race, or ethnicity. We also believe that all manufacturers should validate their pulse oximeters on patients of all skin colors.
NHCSL BBA Contact
Vice President, Government Relations & Public Policy